Comparison of tacrolimus levels in saliva and blood serum of patients after heart transplantation

Document Type : Original Article

Authors

1 Department of Thoracic Surgery, Faculty of Medicine, Mashhad University of Medical Sciences,Mashhad, Iran

2 Lung Diseases Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Clinical Pharmacy Department, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

4 Vascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Cardiac Surgery, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

6 Department of Anesthesiology, Lung Diseases Research Center, School of Medicine, Mashhad University of Medical Science , Mashhad, Iran

7 Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

8 Lung disease Research Center, Emam Reza hospital, Mashhad university of medical science, Mashhad, Iran

Abstract

Introduction: Considering that the lack of correct understanding of tacrolimus serum levels leads to irreversible complications such as kidney failure, convulsions, etc. in heart transplant patients, it is very important to understand the factors affecting the metabolism and serum levels of this drug. In addition, saliva can be used as a more accessible source to measure tacrolimus levels.
Materials and Methods: In our study, 7 patients including 4 men and 3 women were included in the study, 3 patients due to DCM, 1 patient due to myocarditis, 1 patient due to ICM, 1 patient due to ARVC and 1 patient due to RHD underwent heart transplant surgery.: In this study, we aim to compare the levels of tacrolimus in the saliva and serum of patients after heart transplantation. We hypothesize that there may be a correlation between the levels of tacrolimus in saliva and serum, as both are potential sources for drug monitoring in heart transplant patients.
Results: Our study highlights the importance of accurately monitoring tacrolimus levels in heart transplant patients. While saliva-based monitoring of tacrolimus levels may be a convenient alternative to blood draw, our findings suggest that it may not provide accurate
Conclusion: These findings indicate that caution should be exercised when using salivary tacrolimus levels as a sole indicator of drug concentration and further research is necessary to better understand and interpret salivary tacrolimus levels in clinical practice and to optimize post-transplant care for heart transplant patients.

Keywords

References

  1. Sikma MA, Van Maarseveen EM, Van De Graaf EA, Kirkels JH, Verhaar MC, Donker DW, et al. Pharmacokinetics and toxicity of tacrolimus early after heart and lung transplantation. American Journal of Transplantation. 2015 Sep 1;15(9):2301-13.
  2. Paschier A, Destere A, Monchaud C, Labriffe M, Marquet P, Woillard JB. Tacrolimus population pharmacokinetics in adult heart transplant patients. British Journal of Clinical Pharmacology. 2023 Dec;89(12):3584-95.
  3. Kirubakaran R, Uster DW, Hennig S, Carland JE, Day RO, Wicha SG, et al. Adaptation of a population pharmacokinetic model to inform tacrolimus therapy in heart transplant recipients. Br J Clin Pharmacol. 2022; 89(3):bcp.15566.
  4. Dasari BV, Hodson J, Nassir A, Widmer J, Isaac J, Mergentel H, et al. Variations in practice to therapeutic monitoring of tacrolimus following primary adult liver transplantation. International journal of organ transplantation medicine. 2016;7(1):1.
  5. Braithwaite HE, Darley DR, Brett J, Day RO, Carland JE. Identifying the association between tacrolimus exposure and toxicity in heart and lung transplant recipients: a systematic review. Transplant Rev. 2021; 35(2):100610.
  6. Undre NA, Stevenson PJ, European Tacrolimus Heart Study Group. Pharmacokinetics of tacrolimus in heart transplantation. Transplant Proc. 2002; 34(5): 1836-38.
  7. Woillard JB, de Winter BCM, Kamar N, Marquet P, Rostaing L, Rousseau A. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations – twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011; 71(3): 391-402.
  8. Pei L, Li R, Zhou H, Du W, Gu Y, Jiang Y, et al. A Physiologically Based Pharmacokinetic Approach to Recommend an Individual Dose of Tacrolimus in Adult Heart Transplant Recipients. Pharmaceutics. 2023 Nov 3;15(11):2580.
  9. MacDonald C, Norris C, Alton GY, Urschel S, Joffe AR, Morgan CJ. Western Canadian Complex Pediatric Therapies Follow-Up Group. Acute kidney injury after heart transplant in young children: risk factors and outcomes. Pediatric Nephrology. 2016 Apr;31:671-8.
  10. Belostotsky V, Adaway J, Keevil BG, Cohen DR, Webb NJ. Measurement of saliva tacrolimus levels in pediatric renal transplant recipients. Pediatric Nephrology. 2011 Jan;26:133-8.
  11. Staatz CE, Tett SE. Clinical pharmacokinetics of once-daily tacrolimus in solid-organ transplant patients. Clinical pharmacokinetics. 2015 Oct;54:993-1025.
  12. Størset E, Åsberg A, Hartmann A, Reisæter AV, Holdaas H, Skauby M, et al. Low‐target tacrolimus in de novo standard risk renal transplant recipients: a single‐centre experience. Nephrology. 2016 Oct;21(10):821-7.
Journal of Cardio-Thoracic Medicine
Volume 12, Issue 1
March 2024
Pages 1290-1294

Files

Share

How to cite

Statistics